Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļSION
āļāļ·āđāļāļāļĢāļīāļĐāļąāļSionna Therapeutics Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 07, 2025
āļāļĩāļāļĩāđāļCloonan (Michael)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ41
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļFeb 07
āļāļĩāđāļāļĒāļđāđ21 Hickory Drive, Suite 500
āđāļĄāļ·āļāļWALTHAM
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02451
āđāļāļĢāļĻāļąāļāļāđ16178192020
āđāļ§āđāļāđāļāļāđhttps://www.sionnatx.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļSION
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļFeb 07, 2025
āļāļĩāļāļĩāđāļCloonan (Michael)
Mr. Michael (Mike) Cloonan
Mr. Michael (Mike) Cloonan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Ms. Jennifer Fitzpatrick, J.D.
Ms. Jennifer Fitzpatrick, J.D.
Chief Legal Officer, Head of Program Management
Chief Legal Officer, Head of Program Management
Ms. Elena H. Ridloff
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
Mr. Paul J. Clancy
Independent Chairman of the Board of Director
Independent Chairman of the Board of Director
Dr. Charlotte McKee, M.D.
Dr. Charlotte McKee, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
Dr. Bruce L. Booth
Independent Director
Dr. H. Edward Fleming, Jr., M.D.
Dr. H. Edward Fleming, Jr., M.D.
Independent Director
Dr. Lucian Iancovici, M.D.
Dr. Lucian Iancovici, M.D.
Independent Director
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Dr. Marcella Kuhlman (Marcie) Ruddy, M.D.
Dr. Marcella Kuhlman (Marcie) Ruddy, M.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Michael (Mike) Cloonan
Mr. Michael (Mike) Cloonan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Ms. Jennifer Fitzpatrick, J.D.
Ms. Jennifer Fitzpatrick, J.D.
Chief Legal Officer, Head of Program Management
Chief Legal Officer, Head of Program Management
Ms. Elena H. Ridloff
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
Mr. Paul J. Clancy
Independent Chairman of the Board of Director
Independent Chairman of the Board of Director
Dr. Charlotte McKee, M.D.
Dr. Charlotte McKee, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
Dr. Bruce L. Booth
Independent Director